| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| pmid: | ||||
| Finch JL et al. | Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone. | 1999 | J. Am. Soc. Nephrol. | pmid:10232683 |
| Goldenberg MM | Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis. | 1999 | Clin Ther | pmid:10321413 |
| Zager RA | Calcitriol directly sensitizes renal tubular cells to ATP-depletion- and iron-mediated attack. | 1999 | Am. J. Pathol. | pmid:10362817 |
| Stephens D et al. | A statistical experimental approach to cosolvent formulation of a water-insoluble drug. | 1999 | Drug Dev Ind Pharm | pmid:10434141 |
| Chen TC et al. | The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer. | 2000 | Clin. Cancer Res. | pmid:10741714 |
| Balint E et al. | Effect of the vitamin D analogues paricalcitol and calcitriol on bone mineral in vitro. | 2000 | Am. J. Kidney Dis. | pmid:11007682 |
| Brown AJ et al. | Calcemic activity of 19-Nor-1,25(OH)(2)D(2) decreases with duration of treatment. | 2000 | J. Am. Soc. Nephrol. | pmid:11053485 |
| Shankar VN et al. | In vitro metabolism of 19-nor-1alpha, 25-(OH)2D2 in cultured cell lines: inducible synthesis of lipid- and water-soluble metabolites. | 2001 | Arch. Biochem. Biophys. | pmid:11370854 |
| Finch JL et al. | Relative potencies of 1,25-(OH)(2)D(3) and 19-Nor-1,25-(OH)(2)D(2) on inducing differentiation and markers of bone formation in MG-63 cells. | 2001 | J. Am. Soc. Nephrol. | pmid:11423575 |
| Moe SM et al. | A placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol. | 2001 | Am. J. Kidney Dis. | pmid:11576883 |
| Martin KJ and González EA | Vitamin D analogues for the management of secondary hyperparathyroidism. | 2001 | Am. J. Kidney Dis. | pmid:11689385 |
| Llach F and Yudd M | Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. | 2001 | Am. J. Kidney Dis. | pmid:11689387 |
| Sprague SM et al. | Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. | 2001 | Am. J. Kidney Dis. | pmid:11689388 |
| Martin KJ et al. | Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study. | 2001 | Am. J. Kidney Dis. | pmid:11689389 |
| Thummel KE et al. | Transcriptional control of intestinal cytochrome P-4503A by 1alpha,25-dihydroxy vitamin D3. | 2001 | Mol. Pharmacol. | pmid:11723248 |
| Martin KJ and González EA | Strategies to minimize bone disease in renal failure. | 2001 | Am. J. Kidney Dis. | pmid:11728986 |
| Cozzolino M et al. | p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium. | 2001 | Kidney Int. | pmid:11737585 |
| Slatopolsky E and Brown AJ | Vitamin D analogs for the treatment of secondary hyperparathyroidism. | 2002 | Blood Purif. | pmid:11803167 |
| Brown AJ et al. | Differential effects of 19-nor-1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport. | 2002 | J. Lab. Clin. Med. | pmid:12032488 |
| Slatopolsky E et al. | Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats. | 2002 | Kidney Int. | pmid:12234297 |
| Bailie GR and Johnson CA | Comparative review of the pharmacokinetics of vitamin D analogues. | 2002 Sep-Oct | Semin Dial | pmid:12358640 |
| Coyne DW et al. | Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. | 2002 | Am. J. Kidney Dis. | pmid:12460048 |
| Molnár I et al. | 19-nor-1alpha,25-dihydroxyvitamin D(2) (paricalcitol): effects on clonal proliferation, differentiation, and apoptosis in human leukemic cell lines. | 2003 | J. Cancer Res. Clin. Oncol. | pmid:12618899 |
| Sprague SM et al. | Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. | 2003 | Kidney Int. | pmid:12631365 |
| Martin CJ and Reams SM | The renal dietitian's role in managing hyperphosphatemia and secondary hyperparathyroidism in dialysis patients: a national survey. | 2003 | J Ren Nutr | pmid:12671837 |
| Slatopolsky E et al. | Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia. | 2003 | Kidney Int. | pmid:12753289 |
| Cardús A et al. | [Differential effect of vitamin D analogues on the proliferation of vascular smooth muscle cells]. | 2003 | Nefrologia | pmid:12778867 |
| Kumagai T et al. | Vitamin D2 analog 19-nor-1,25-dihydroxyvitamin D2: antitumor activity against leukemia, myeloma, and colon cancer cells. | 2003 | J. Natl. Cancer Inst. | pmid:12813173 |
| Teng M et al. | Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. | 2003 | N. Engl. J. Med. | pmid:12890843 |
| Drüeke TB and McCarron DA | Paricalcitol as compared with calcitriol in patients undergoing hemodialysis. | 2003 | N. Engl. J. Med. | pmid:12890849 |
| Dunlap N et al. | 1alpha,25-dihydroxyvitamin D(3) (calcitriol) and its analogue, 19-nor-1alpha,25(OH)(2)D(2), potentiate the effects of ionising radiation on human prostate cancer cells. | 2003 | Br. J. Cancer | pmid:12915889 |
| Schroeder NJ et al. | Effects of 'non-calcaemic' vitamin D analogues on 24-hydroxylase expression in MG-63 osteoblast-like cells. | 2003 | Nephron Physiol | pmid:12972708 |
| Colussi G | Paricalcitol, calcitriol, and survival of patients undergoing hemodialysis. | 2003 | N. Engl. J. Med. | pmid:14614175 |
| Kida Y | Paricalcitol, calcitriol, and survival of patients undergoing hemodialysis. | 2003 | N. Engl. J. Med. | pmid:14626256 |
| Ratnam S et al. | Paricalcitol, calcitriol, and survival of patients undergoing hemodialysis. | 2003 | N. Engl. J. Med. | pmid:14626257 |
| Drüeke TB | Calcimimetics versus vitamin D: what are their relative roles? | 2004 | Blood Purif. | pmid:14732810 |
| Dobrez DG et al. | Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. | 2004 | Nephrol. Dial. Transplant. | pmid:15004264 |
| Durakovic C et al. | Topical paricalcitol (19-nor-1 alpha,25-dihydroxyvitamin D2) is a novel, safe and effective treatment for plaque psoriasis: a pilot study. | 2004 | Br. J. Dermatol. | pmid:15270890 |
| Petrie MS et al. | Production of plasminogen activator inhibitor-1 (PAI-1) by endothelial cells: differential responses to calcitriol and paricalcitol. | 2004 | J. Thromb. Haemost. | pmid:15613047 |
| Salusky IB | Are new vitamin D analogues in renal bone disease superior to calcitriol? | 2005 | Pediatr. Nephrol. | pmid:15690188 |
| Teng M et al. | Activated injectable vitamin D and hemodialysis survival: a historical cohort study. | 2005 | J. Am. Soc. Nephrol. | pmid:15728786 |
| Robinson DM and Scott LJ | Paricalcitol: a review of its use in the management of secondary hyperparathyroidism. | 2005 | Drugs | pmid:15733015 |
| Kumagai T et al. | 19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia. | 2005 | Cancer Res. | pmid:15781666 |
| Robinson DM and Scott LJ | Spotlight on paricalcitol in secondary hyperparathyroidism. | 2005 | Treat Endocrinol | pmid:15898824 |
| Li H et al. | Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 | Chem. Res. Toxicol. | pmid:15962942 |
| Ruth Wu-Wong J et al. | Vitamin D analogs down-regulate plasminogen activator inhibitor-1 in human coronary artery smooth muscle cells. | 2005 | J. Thromb. Haemost. | pmid:15978119 |
| Bover J et al. | [New therapeutic strategies in secondary hyperparathyroidism on dialysis (II): vitamin D analogues and calcium-mimetics]. | 2005 | Nefrologia | pmid:16050413 |
| Andress DL | Vitamin D treatment in chronic kidney disease. | 2005 Jul-Aug | Semin Dial | pmid:16076355 |
| Wu-Wong JR et al. | Effects of Vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells. | 2006 | Atherosclerosis | pmid:16095599 |
Paricalcitol
Paricalcitol is a lipid of Sterol Lipids (ST) class. Paricalcitol is associated with abnormalities such as Vitamin D Deficiency. The involved functions are known as Hypertrophy, Left Ventricular. Paricalcitol often locates in Blood.
Cross Reference
Introduction
To understand associated biological information of Paricalcitol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Paricalcitol?
Paricalcitol is suspected in Vitamin D Deficiency and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
No disease MeSH terms mapped to the current reference collection.
PubChem Associated disorders and diseases
What pathways are associated with Paricalcitol
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Paricalcitol?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Paricalcitol?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Paricalcitol?
There are no associated biomedical information in the current reference collection.
What genes are associated with Paricalcitol?
There are no associated biomedical information in the current reference collection.
What common seen animal models are associated with Paricalcitol?
There are no associated biomedical information in the current reference collection.